UPDATE: ABIOMED (ABMD) PT Raised to $300 at Stephens

(Updated - April 9, 2018 8:06 AM EDT)

Stephens raised its price target on ABIOMED (NASDAQ: ABMD) to $300.00 (from $274.00) while maintaining a Overweight rating. The revised price target assumes an EV/CY19E revenue multiple of approximately 14.0x.

Stephens maintained FY18 and FY19 revenue and earnings estimates. Specifically, FY18 revenue and earnings estimates of $583.2 million and $2.24 remain unchanged.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Ford (F) earnings top estimates in Q1 amid strength in Pro unit; stock up
• Bunzl Plc. (BNZL:LN) (BZLFY) PT Raised to GBP33 at JPMorgan
• Goldman Sachs on Meta Platforms Inc. (META): 'We expect investors to have an initial negative reaction'